Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

241
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
241
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.6K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

295
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
295
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

481
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
481
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

333
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
333

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measuring What Matters: Hospitalisation Reduction in COPD.

American journal of respiratory and critical care medicine·2026
Same author

Time for course correction? Rethinking oral steroids duration in acute asthma.

Thorax·2026
Same author

Monoclonal antibody therapy in chronic obstructive pulmonary disease: will it prevent hospitalizations?

American journal of respiratory and critical care medicine·2026
Same author

Blood Eosinophil Counts in Healthy Volunteers and in Patients with Asthma and COPD in India: A Multi-Centre Cross-Sectional Report.

International journal of chronic obstructive pulmonary disease·2025
Same author

Fractional exhaled nitric oxide and the response to prednisolone for asthma attacks in patients treated with anti-IL5/5Rα therapy: a prospective observational study.

The European respiratory journal·2025
Same author

Type 2 inflammatory biomarkers in asthma and COPD: what we think we know.

The European respiratory journal·2025

Related Experiment Video

Updated: Jul 16, 2025

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
00:07

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

9.7K

Prednisolone for COPD exacerbations: time for a rethink.

Sanjay Ramakrishnan1,2

  • 1Oxford NIHR Biomedical Research Centre and Nuffield Department of Medicine, University of Oxford, Oxford, UK.

ERJ Open Research
|September 13, 2023
PubMed
Summary

Universal prednisolone treatment for chronic obstructive pulmonary disease (COPD) exacerbations offers no benefits and causes harm. Blood eosinophil-guided therapy is recommended for COPD exacerbations.

More Related Videos

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

732
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.0K

Related Experiment Videos

Last Updated: Jul 16, 2025

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
00:07

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

9.7K
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

732
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.0K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Medicine

Background:

  • Chronic obstructive pulmonary disease (COPD) exacerbations are frequently treated with systemic corticosteroids like prednisolone.
  • Universal application of prednisolone in COPD exacerbations is a common clinical practice.
  • The efficacy and safety of universal corticosteroid use in COPD require critical evaluation.

Discussion:

  • Systemic corticosteroids, including prednisolone, are associated with significant adverse effects.
  • The benefits of broad prednisolone administration for all COPD exacerbations are questionable.
  • Biomarkers such as blood eosinophil counts can potentially guide steroid therapy.

Key Insights:

  • Universal prednisolone treatment for COPD exacerbations provides no clinical benefit.
  • Widespread use of prednisolone in COPD exacerbations leads to patient harm.
  • Blood eosinophil counts can identify patients who may benefit from prednisolone.

Outlook:

  • Implementing blood eosinophil-guided prednisolone treatment can optimize COPD exacerbation management.
  • Personalized medicine approaches are crucial for improving COPD patient outcomes.
  • Further research should focus on refining biomarker-guided therapies for respiratory diseases.